Addus HomeCare (ADUS)
(Delayed Data from NSDQ)
$128.72 USD
-4.31 (-3.24%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $128.78 +0.06 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$128.72 USD
-4.31 (-3.24%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $128.78 +0.06 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Zacks News
Implied Volatility Surging for Addus HomeCare (ADUS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Addus HomeCare (ADUS) stock based on the movements in the options market lately.
3 Stocks to Watch From the Pandemic-Hit Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. AMED, ADUS and HNGR are well poised to gain from the prospects.
Addus HomeCare (ADUS) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.11% and 1.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Reports Next Week: What You Should Expect
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.42% and 4.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Tops Q1 Earnings Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.32% and 0.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Addus HomeCare (ADUS) Stock Jumps 6.5%: Will It Continue to Soar?
by Zacks Equity Research
Addus HomeCare (ADUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Tenet Healthcare (THC) Drops Plans to Spin Off Conifer Segment
by Zacks Equity Research
Tenet Healthcare (THC) aborts its Conifer spin-off plan based on its solid business opportunities and strong pipeline prospects. It also reaffirmed its 2022 guidance.
How Much Upside is Left in Addus HomeCare (ADUS)? Wall Street Analysts Think 62%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 61.5% in Addus HomeCare (ADUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Addus HomeCare (ADUS) Matches Q4 Earnings Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 0% and 1.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADUS or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. CHE: Which Stock Is the Better Value Option?
Addus HomeCare (ADUS) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of -2.15% and -5.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Addus HomeCare (ADUS) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.12% and -0.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Addus HomeCare (ADUS) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 4.23% and -1.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Addus HomeCare (ADUS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Addus HomeCare, LHC Group and Amedisys
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Addus HomeCare, LHC Group and Amedisys
Biden Chips in $400B for Home Healthcare: Stocks to Watch
by Sapna Bagaria
Biden's support to expand access to long-term care services under Medicaid bodes well for companies providing home healthcare.
Is a Surprise Coming for Addus HomeCare (ADUS) This Earnings Season?
by Zacks Equity Research
Addus HomeCare (ADUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Encompass Health (EHC) Gain From Inpatient Rehab Business?
by Zacks Equity Research
Encompass Health (EHC) is resorting to business restructuring to focus on core growth areas, which should expand its returns.
Align (ALGN) Rides on Robust Invisalign Sales Amid Coronavirus
by Zacks Equity Research
Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.
CVS Health's (CVS) Front Store Sales Robust, LTC Suffers
by Zacks Equity Research
CVS Health's (CVS) Health Care Benefits arm benefits from strong Medicare annual enrollment period.